DOCSLIB.ORG

BCR-ABL-Induced Transformation (Adaptor Protein/Leukemia/Ras/Protein-Tyrosine Kinase/Signaling) MIKHAIL L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BCR-ABL-Induced Transformation (Adaptor Protein/Leukemia/Ras/Protein-Tyrosine Kinase/Signaling) MIKHAIL L Proc. Natl. Acad. Sci. USA Vol. 92, pp. 10889-10893, November 1995 Medical Sciences Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation (adaptor protein/leukemia/Ras/protein-tyrosine kinase/signaling) MIKHAIL L. GISHIZKY*t, DAVID CORTEZt, AND ANN MARIE PENDERGASTt *Department of Hematology/Oncology, SUGEN, Inc., 515 Galveston Drive, Redwood City, CA 94063; and tDepartment of Pharmacology, Duke University Medical Center, Durham, NC 27710 Communicated by H. Hanafusa, Rockefeller Institute, New York NY July 11, 1995 (received for review November 9, 1994) ABSTRACT Growth factor-binding protein 2 (Grb2) is an BCR-ABL is a chimeric oncogene implicated in the patho- adaptor protein that links tyrosine kinases to Ras. BCR-ABL genesis of Philadelphia chromosome (Ph')-positive human is a tyrosine kinase oncoprotein that is implicated in the leukemias. The BCR-ABL oncogene is formed by the recip- pathogenesis of Philadelphia chromosome (Ph')-positive leu- rocal translocation of sequences from the ABL gene on kemias. Grb2 forms a complex with BCR-ABL and the nu- chromosome 9 into BCR sequences on chromosome 22 (6). cleotide exchange factor Sos that leads to the activation of the This translocation can generate two chimeric proteins, p185 Ras protooncogene. In this report we demonstrate that Grb2 and p210, that exhibit increased tyrosine kinase activity com- mutant proteins lacking amino- or carboxyl-terminal src homol- pared with the normal ABL protein (7, 8). A strong correlation ogy SH3 domains suppress BCR-ABL-induced Ras activation exists between the oncogenic potency and tyrosine kinase and reverse the oncogenic phenotype. The Grb2 SB13-deletion activity of BCR-ABL proteins and their ability to activate Ras mutant proteins bind to BCR-ABL and do not impair tyrosine (9, 10). Previously, we and others demonstrated that Grb2 kinase activity. Expression of the Grb2 SH3-deletion mutant forms a complex with BCR-ABL in vivo (9, 11). This associ- proteins in BCR-ABLtransformed Rat-i fibroblasts and in the ation is mediated by direct binding of the Grb2 SH2 domain to human Ph'-positive leukemic cell line K562 inhibits their ability Tyr-177 in the BCR portion of BCR-ABL. Mutant BCR-ABL to grow as foci in soft agar and form tumors in nude mice. that carries the Tyr-177 -> Phe change no longer binds Grb2 Furthermore, expression of the Grb2 SH3-deletion mutants in (9) and is impaired in its ability to activate Ras (9) and to K562 cells induced their differentiation. Because Ras plays an induce cellular transformation in Rat-1 cells (9, 12). This important role in signaling by receptor and nonreceptor tyrosine implicates Grb2 as a potential regulator of BCR-ABL-induced kinases, the use of interfering mutant Grb2 proteins may be oncogenesis. applied to block the proliferation ofother cancers that depend in We report that Grb2 proteins lacking either the amino- or part on activated tyrosine kinases for growth. carboxyl-terminal SH3 domain can inhibit BCR-ABL-induced transformation. The ability of the Grb2 mutants to reverse the A central issue in the study of oncogenesis is to identify the key transformed phenotype correlates with their ability to inhibit effectors responsible for transmitting the mitogenic stimulus Ras activation. Expression of Grb2 mutant proteins in the induced by activated protein tyrosine kinases. Tyrosine kinases human Ph1-positive chronic myelogenous leukemia (CML) associate with a variety of cytoplasmic proteins through phos- cell line K562 induced the cells to differentiate. These data photyrosine-dependent and -independent protein-binding do- suggest that BCR-ABL transforms hematopoietic cells in part mains, the best characterized of which are the src homology by blocking differentiation and inducing proliferation in a domains SH2 and SH3 (1, 2). An increasingly important group Ras-dependent manner. of SH2/SH3-containing proteins are the "adaptor" proteins such as growth factor-binding protein 2 (Grb2)/sem-5, the P85 subunit of phosphatidylinositol 3-kinase (PI3-K), Nck, Crkl, MATERIALS AND METHODS and Crk (2). These molecules consist almost exclusively of Cells and Viruses. The Ph'-positive K562 cell line was protein-binding domains and appear to function as "connec- maintained in RPMI medium with 10% (vol/vol) fetal calf tors" integrating mitogenic and other extracellular signals serum. Rat-1 fibroblasts were grown in Dulbecco's modified among multiple intracellular signaling pathways. The strongest Eagle's medium (DMEM) with 5% fetal calf serum. BCR- evidence implicating adaptor proteins as critical components ABL transformed Rat-1 fibroblasts were established as de- in signal transduction cascades has been obtained from studies scribed (13). of Grb2 (3). Helper-free retroviral stocks were prepared by transient Grb2 is the human homolog of the Caenorhabditis elegans hyperexpression in COS cells as described (8). gene sem-5 and functions by directly coupling tyrosine kinases Antibodies. Anti-ABL rabbit polyclonal antibodies were to the Ras-activating nucleotide exchange factor Sos (3, 4). used for immunoprecipitation (7). A mouse anti-ABL mono- Mammalian Grb2 is a 26-kDa protein composed of a single clonal antibody (designated 21-63) was used for immunoblot- SH2 domain flanked by SH3 domains on the amino and ting (9). Grb2 proteins were detected by immunoblotting carboxyl termini (3). The Grb2 SH2 domain binds to phos- (Western blotting) of total cell lysates with an anti-Grb2 mouse phorylated tyrosine residues on tyrosine kinases and other monoclonal antibody (Transduction Laboratories, Lexington, proteins, while the SH3 domains bind to proline-rich se- KY). Epitope-tagged Grb2 proteins were also detected with quences of Sos (5). The ability of mammalian Grb2 gene to the 12CA5 mouse monoclonal antibody against influenza complement loss-of-function mutations in the C. elegans gene hemagglutinin [Babco (Emeryville, CA) or Boehringer Mann- sem-5 suggests that Grb2 is an essential element in the tyrosine heim]. kinase-stimulated mitogenic response (5). Abbreviations: SH3, src homology 3; SH2 src homology 2; CML The publication costs of this article were defrayed in part by page charge chronic myelogenous leukemia; Grb2, growth factor-binding protein 2; payment. This article must therefore be hereby marked "advertisement" in HA, hemagglutinin. accordance with 18 U.S.C. §1734 solely to indicate this fact. tTo whom reprint requests should be addressed. 10889 Downloaded by guest on September 29, 2021 10890 Medical Sciences: Gishizky et al. Proc. Natl. Acad. Sci. USA 92 (1995) Plasmid Constructions. Full-length human Grb2 cDNA or tcli c\ Grb2 mutants lacking the 5' or 3' SH3 domains were inserted CM O( c! o .0 in-frame into the BamHI site of a modified pCGn plasmid (D z c) 4 vector (14). The hygromycin-resistance gene was inserted CD < < > upstream of the simian virus 40 (SV40) origin of replication. o o 0 0 The constructs were verified by dideoxy chain-termination a ca sequence analysis. pZipNeoSV and pZipRas-Asnl7 have been Autokinase described (15). Transfections. Grb2 constructs were transfected into Rat-1, Bcr/Abl 0 Rat-1/BCR-ABL, and Rat-1/Raf' cells by the standard cal- - 205 cium phosphate transfection protocol (8, 9). K562 cells were transfected by electroporation with a Gene Pulser Electropo- rator (Bio-Rad). Transformation Assays. Soft agar assays were performed as - 116 described (9, 13). Liquid culture foci formation assays were performed by standard procedures. After transfection, cells - 80 were cultured for 24 hr, trypsinized, and replated at 1 X 105 cells per 10-cm2 dish in the presence of hygromycin at 250 ,ug/ml. Cells transfected with pZipNeoSV and pZipRas- Anti-Grb2 were cultured in the presence at (Asnl7) of G418 (Sigma) 0.5 Western - 49.5 mg/ml. The number of foci in each culture was determined 12-14 days later. Transcriptional Activation Assay. Transcriptional activation - 32.5 of expression from a Ras-responsive element (ets/AP-1) pro- moter was performed as described (9). endogenous oe Ras-Bound Guanine Nucleotide Ratio Determination. The Grb2 "- _ _ -27.5 procedure for assaying the percentage of GTP bound to Ras was essentially as described (16). The' amount of labeled GTP 41M and GDP in each sample was quantitated on a Betagen - 18.5 phosphor imager. The percent of GTP bound to Ras in each 1 2 34 sample was calculated as GTP/(GTP + GDP). FIG. 1. Expression of p210 BCR-ABL and Grb2 wild-type (WT) Binding Assays, in Vitro Autophosphorylation, and Immu- and mutant proteins in Rat-1 fibroblasts. Samples correspond to mass noblotting. Procedures for in vitro binding assays, in vitro populations of Rat-1/BCR-ABL cells transfected with the following labeling with [y-32P]ATP, and immunoblotting were carried plasmid DNAs: WT Grb2 (lane 1), AC-GRB2 (lane 2), AN-GRB2 out essentially as described (9). (lane 3), and an empty vector (lane 4). (Upper) Cells were lysed and Hemoglobin Protein Determinations. The amount of hemo- immunoprecipitated with anti-ABL pex4 antibodies, and the immu- globin present in mass populations of transfected K562 cells noprecipitates were subjected to an in vitro autokinase assay (9). was determined essentially as described (17). (Lower) Grb2 proteins were detected by Western blotting of total cell lysates with an anti-Grb2 mouse monoclonal antibody and visualized with the enhanced chemiluminescence detection system. The greater RESULTS size of the transfected wild-type Grb2 protein is due to the fusion of HA Grb2 Mutants Reverse the Oncogenic Phenotype of BCR- the epitope tag. ABL-Transformed Rat-i Fibroblasts. Mutant Grb2 genes tions of transfected Rat-1/BCR-ABL cells were evaluated for were constructed that deleted the SH3 domain on either the growth in liquid culture and in soft agar. amino (AN) or carboxyl (AC) terminus. To facilitate discrim- Expression of the AN-Grb2 mutant protein in Rat-1/BCR- ination of endogenous Grb2 protein from the transfected ABL cells caused reversion to a nontransformed phenotype.
Load more

Recommended publications
  • Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector
    Author Manuscript Published OnlineFirst on October 11, 2017; DOI: 10.1158/0008-5472.CAN-17-1487 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Paxillin binding to the cytoplasmic domain of CD103 promotes cell adhesion and effector functions for CD8+ resident memory T cells in tumors Ludiane Gauthier1, Stéphanie Corgnac1, Marie Boutet1, Gwendoline Gros1, Pierre Validire2, Georges Bismuth3 and Fathia Mami-Chouaib1 1 INSERM UMR 1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, EPHE, Fac. de médecine - Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France 2 Institut Mutualiste Montsouris, Service d’Anatomie pathologique, 75014 Paris, France. 3 INSERM U1016, CNRS UMR8104, Université Paris Descartes, Institut Cochin, 75014 Paris. S Corgnac, M Boutet and G Gros contributed equally to this work. M Boutet current address: Department of Microbiology and Immunology Albert Einstein College of Medecine, NY 10461 USA. Corresponding author: Fathia Mami-Chouaib, INSERM UMR 1186, Gustave Roussy. 39, rue Camille Desmoulins, F-94805 Villejuif. Phone: +33 1 42 11 49 65, Fax: +33 1 42 11 52 88, e-mail: [email protected] and [email protected] Running title: CD103 signaling in human TRM cells Key words: TRM cells, CD103 integrin, T-cell function and signaling, paxillin. Abbreviations: IS: immune synapse; LFA: leukocyte function-associated antigen; FI: fluorescence intensity; mAb: monoclonal antibody; phospho: phosphorylated; Pyk2: proline- rich tyrosine kinase-2; NSCLC: non-small-cell lung carcinoma; r: recombinant; sh-pxn: shorthairpin RNA-paxillin; TCR: T-cell receptor; TIL: tumor-infiltrating lymphocyte; TRM: tissue-resident memory T.
    [Show full text]
  • Paxillin: a Focal Adhesion-Associated Adaptor Protein
    Oncogene (2001) 20, 6459 ± 6472 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Paxillin: a focal adhesion-associated adaptor protein Michael D Schaller*,1 1Department of Cell and Developmental Biology, Lineberger Comprehensive Cancer Center and Comprehensive Center for In¯ammatory Disorders, University of North Carolina, Chapel Hill, North Carolina, NC 27599, USA Paxillin is a focal adhesion-associated, phosphotyrosine- The molecular cloning of paxillin revealed a number containing protein that may play a role in several of motifs that are now known to function in mediating signaling pathways. Paxillin contains a number of motifs protein ± protein interactions (see Figure 1) (Turner that mediate protein ± protein interactions, including LD and Miller, 1994; Salgia et al., 1995a). The N-terminal motifs, LIM domains, an SH3 domain-binding site and half of paxillin contains a proline-rich region that SH2 domain-binding sites. These motifs serve as docking could serve as an SH3 domain-binding site. Several sites for cytoskeletal proteins, tyrosine kinases, serine/ tyrosine residues conforming to SH2 domain binding threonine kinases, GTPase activating proteins and other sites were also noted. In addition, the N-terminal adaptor proteins that recruit additional enzymes into domain of paxillin contains ®ve copies of a peptide complex with paxillin. Thus paxillin itself serves as a sequence, called the LD motif, which are now known docking protein to recruit signaling molecules to a to function as binding sites for other proteins (see speci®c cellular compartment, the focal adhesions, and/ Table 1) (Brown et al., 1998a). The C-terminal half of or to recruit speci®c combinations of signaling molecules paxillin is comprised of four LIM domains, which are into a complex to coordinate downstream signaling.
    [Show full text]
  • Download PDF to Print
    MOLECULAR INSIGHTS IN PATIENT CARE A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications Sanjeev Kumar Gupta, MD1,*; Nitin Jain, MD1,*; Guilin Tang, MD, PhD2; Andrew Futreal, PhD3; Sa A. Wang, MD2; Joseph D. Khoury, MD2; Richard K. Yang, MD, PhD2; Hong Fang, MD2; Keyur P.Patel, MD, PhD2; Rajyalakshmi Luthra, PhD2; Mark Routbort, MD, PhD2; Bedia A. Barkoh, MS2; Wei Chen, MS2; Xizeng Mao, PhD3; Jianhua Zhang, PhD3; L. Jeffrey Medeiros, MD2; Carlos E. Bueso-Ramos, MD, PhD2; and Sanam Loghavi, MD2 Background ABSTRACT Myeloid and lymphoid neoplasms with eosinophilia and gene rearrangement constitute a distinct group RNA-seq was used to identify the partner gene and confirm the of hematologic neoplasms in the current WHO clas- BCR-PDGFRB fi presence of a fusion. Identi cation of this fusion sification for hematopoietic neoplasms.1 Included in product resulted in successful treatment and long-term remission of this myeloid neoplasm. Based on our results, we suggest that despite this category are neoplasms harboring abnormal current WHO recommendations, screening for PDGFRB rearrange- gene fusions involving PDGFRA, PDGFRB,andFGFR1 ment in cases of leukocytosis with eosinophilia and no other etiologic or PCM1-JAK2. These fusions result in constitutive explanation is necessary, even if the karyotype is normal. activation of respective tyrosine kinases that can J Natl Compr Canc Netw 2020;18(10):1300–1304 be targeted using specific kinase inhibitors. There doi: 10.6004/jnccn.2020.7573 are multiple recognized partner genes for PDGFRA, PDGFRB, FGFR1, and JAK2. PDGFRB located at chro- mosome 5q32 has .25knownfusionpartners,with ETV6 the most common.2–8 Although PDGFRA re- arrangements often can be cryptic and not readily observed on routine karyotyping studies,9,10 PDGFRB rearrangements are believed to be nearly always vis- ible on routine karyotype.
    [Show full text]
  • Real-Time Quantification of BCR-ABL Mrna Transcripts Using the Lightcycler-T(9;22) Quantification Kit
    real-time-quantification 09.05.2000 19:18 Uhr Seite 8 Real-time Quantification of BCR-ABL mRNA Transcripts Using the LightCycler-t(9;22) Quantification Kit Heiko Wittor 1, Hermann Leying 1, Andreas Hochhaus 2, and Rob van Miltenburg 1 1 Roche Molecular Biochemicals, Penzberg, Germany 2 III. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany ly different starting concentrations, so that the initial Introduction target concentration can be determined in a single PCR. The concentration of BCR-ABL transcripts is determi- Literature indicates that in 95 % of all subjects with ned relative to the number of transcripts of a control chronic myeloid leukemia (CML) and in 25-30 % of gene, glucose-6-phosphate dehydrogenase (G6PDH). subjects with acute lymphoblastic leukemia (ALL) a The entire procedure from sample preparation to reciprocal translocation between the long arms of quantitative result is performed in 4.5 hours. chromosome 9 and chromosome 22 [t(9;22)] can be found. This translocation or the resulting fusion pro- duct can be detected by a number of techniques, CLER including fluorescent in situ hybridization, Southern CY blotting, western blotting and reverse transcriptase TThe LightCycler System polymerase chain reaction (RT-PCR). Of these techni- The LightCycler System is based on the amplification LIGHT ques, RT-PCR for the chimeric fusion transcript BCR- of target sequences using alternating heated and ABL has received most attention in relation to the ambient temperature cycles. Samples are contained in detection of minimal residual disease because of its glass capillaries with high surface-to-volume ratio, high sensitivity (1).
    [Show full text]
  • Regulation of B Cell Receptor-Dependent NF-Κb Signaling by the Tumor Suppressor KLHL14
    Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14 Jaewoo Choia, James D. Phelana, George W. Wrightb, Björn Häuplc,d,e, Da Wei Huanga, Arthur L. Shaffer IIIa, Ryan M. Younga, Zhuo Wanga, Hong Zhaoa, Xin Yua, Thomas Oellerichc,d,e, and Louis M. Staudta,1 aLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; bBiometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; cDepartment of Medicine II, Hematology/Oncology, Goethe University, 60590 Frankfurt, Germany; dGerman Cancer Consortium/German Cancer Research Center, 69120 Heidelberg, Germany; and eDepartment of Molecular Diagnostics and Translational Proteomics, Frankfurt Cancer Institute, 60596 Frankfurt, Germany Contributed by Louis M. Staudt, January 29, 2020 (sent for review December 4, 2019; reviewed by Shiv Pillai and Michael Reth) The KLHL14 gene acquires frequent inactivating mutations in ma- by ibrutinib, suggesting that it may be a critical target of this ture B cell malignancies, especially in the MYD88L265P, CD79B mu- drug (8). tant (MCD) genetic subtype of diffuse large B cell lymphoma Genetic analysis revealed recurrent mutations of the KLHL14 (DLBCL), which relies on B cell receptor (BCR) signaling for survival. gene in DLBCL, often in ABC tumors of the MCD genetic However, the pathogenic role of KLHL14 in DLBCL and its molec- subtype (2) and in PCNSL (6, 9). KLHL14 (also known as ular function are largely unknown. Here, we report that KLHL14 is in Printor) (10) belongs to the Kelch-like family of proteins that can close proximity to the BCR in the endoplasmic reticulum of MCD cell serve as subunits of Cullin-RING ubiquitin ligase (CRL) com- line models and promotes the turnover of immature glycoforms of plex (reviewed in ref.
    [Show full text]
  • The BCR Gene and Philadelphia Chromosome-Positive Leukemogenesis
    [CANCER RESEARCH 61, 2343–2355, March 15, 2001] Review The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis Eunice Laurent, Moshe Talpaz, Hagop Kantarjian, and Razelle Kurzrock1 Departments of Bioimmunotherapy [E. L., M. T., R. K.] and Leukemia [H. K., R. K.], University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 Introduction Recent investigations have rapidly added crucial new insights into BCR-related Genes the complex functions of the normal BCR gene and of the BCR-ABL Several BCR-related pseudogenes (BCR2, BCR3, and BCR4) have chimera and are yielding potential therapeutic breakthroughs in the also been described (34). They are not translated into proteins. All of treatment of Philadelphia (Ph) chromosome-positive leukemias. The these genes have been mapped to chromosome 22q11 by in situ term “breakpoint cluster region (bcr)” was first applied to a 5.8-kb hybridization. The orientation is such that BCR2 is the most centro- span of DNA on the long arm of chromosome 22 (22q11), which is 2 meric, followed by BCR4, then BCR1 (the functional gene) and BCR3. disrupted in patients with CML bearing the Ph translocation [t(9; BCR2 and BCR4 are retained on chromosome 22 during the t(9;22) 22)(q34;q11); Refs. 1–3]. Subsequent studies demonstrated that the translocation. The BCR-related genes all contain 3Ј sequences iden- 5.8-kb fragment resided within a central region of a gene designated tical to those encompassing the last seven exons of the BCR1 gene BCR (4). It is now well established that the breakpoint within BCR can (34, 36).
    [Show full text]
  • Abnormality of C-Kit Oncoprotein in Certain Patients with Chronic
    Leukemia (2002) 16, 170–177 2002 Nature Publishing Group All rights reserved 0887-6924/02 $25.00 www.nature.com/leu Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia – potential clinical significance K Inokuchi, H Yamaguchi, M Tarusawa, M Futaki, H Hanawa, S Tanosaki and K Dan Division of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan Chronic myelogenous leukemia (CML) is characterized by the patients, there are two bcr/abl mRNAs for P210BCR/ABL, one Philadelphia (Ph) chromosome and bcr/abl gene rearrangement with and one without exon b3 (b3-a2 type and b2-a2 type).4 which occurs in pluripotent hematopoietic progenitor cells expressing the c-kit receptor tyrosine kinase (KIT). To elucidate In a smaller number of CML patients, there are two other types the biological properties of KIT in CML leukemogenesis, we of bcr/abl mRNAs based on the breakpoint positions of the performed analysis of alterations of the c-kit gene and func- bcr gene, ie m-bcr and ␮-bcr for P190BCR/ABL and P230BCR/ABL, tional analysis of altered KIT proteins. Gene alterations in the respectively.5,6 Extensive studies have been performed on the c-kit juxtamembrane domain of 80 CML cases were analyzed subtypes of the bcr/abl gene and their relation to the prognosis by reverse transcriptase and polymerase chain reaction-single and clinical features.7,8 The established findings regarding the strand conformation polymorphism (RT-PCR-SSCP). One case had an abnormality at codon 564 (AAT→AAG, Asn→Lys), and influence of the subtype of the bcr/abl gene (b3-a2 or b2-a2) six cases had the same base abnormality at codon 541 on the clinical characteristics have been similar for each sub- (ATG→CTG, Met→Leu) in the juxtamembrane domain.
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]
  • And an Imatinib-Responsive Myeloproliferative Disorder1
    [CANCER RESEARCH 64, 2673–2676, April 15, 2004] Advances in Brief NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder1 Jose´L. Vizmanos,1 Francisco J. Novo,1 Jose´P. Roma´n,1 E. Joanna Baxter,2 Idoya Lahortiga,1 Marı´a J. Larra´yoz,1 Marı´a D. Odero,1 Pilar Giraldo,3 Marı´a J. Calasanz,1 and Nicholas C. P. Cross2 1Department of Genetics, University of Navarra, Pamplona, Spain; 2Wessex Regional Genetics Laboratory, Salisbury and Human Genetics Division, University of Southampton, Southampton, United Kingdom; and 3Haematology Service, Miguel Servet Hospital, Zaragoza, Spain Abstract mesylate (4–7) although this drug is inactive against FGFR1 fusions (8). Consequently, identification of patients with PDGFRB rearrange- We describe a new PDGFRB fusion associated with a t(5;14)(q33;q24) ments is very important for their clinical management. Rearrangement in a patient with a longstanding chronic myeloproliferative disorder with of PDGFRB was first described in patients with the t(5;12)(q31;p12), eosinophilia. After confirmation of PDGFRB involvement and definition of the chromosome 14 breakpoint by fluorescence in situ hybridization, leading to the formation of the ETV6-PDGFRB fusion (9). Subse- candidate partner genes were selected on the basis of the presence of quently, PDGFRB has been found fused to CEV14/TRIP11 by the predicted oligomerization domains believed to be an essential feature of t(5;14)(q31;p12) (Ref. 10); HIP1 by the t(5;7)(q33;q11.2) (Ref.
    [Show full text]
  • Imatinib Independent Aberrant Methylation of NOV/CCN3 In
    Vatanmakanian et al. Cell Communication and Signaling (2019) 17:38 https://doi.org/10.1186/s12964-019-0350-6 RESEARCH Open Access Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function? Mousa Vatanmakanian, Mahmood Tavallaie and Shirin Ghadami* Abstract Background: The NOV gene product, CCN3, has been reported in a diverse range of tumors to serve as a negative growth regulator, while acting as a tumor suppressor in Chronic Myelogenous Leukemia (CML). However, the precise mechanism of its silencing in CML is poorly understood. In the current study, we aimed to query if the gene regulation of CCN3 is mediated by the promoter methylation in the patients with CML. In addition, to clarify whether the epigenetic silencing is affected by BCR-ABL1 inhibition, we assessed the methylation status in the patients at different time intervals following the tyrosine kinase inhibition using imatinib therapy, as the first-line treatment for this type of leukemia. Methods: To address this issue, we applied bisulfite-sequencing technique as a high-resolution method to study the regulatory segment of the CCN3 gene. The results were analyzed in newly diagnosed CML patients as well as following imatinib therapy. We also evaluated the correlation of CCN3 promoter methylation with BCR-ABL1 levels. Results: Our findings revealed that the methylation occurs frequently in the promoter region of CML patients showing a significant increase of the methylated percentage at the CpG sites compared to normal individuals. Interestingly, this hypermethylation was indicated to be independent of BCR-ABL1 titers in both groups, which might suggest a mechanism beyond the BCR-ABL1 function.
    [Show full text]
  • BCR Gene BCR, Rhogef and Gtpase Activating Protein
    BCR gene BCR, RhoGEF and GTPase activating protein Normal Function The BCR gene provides instructions for making a protein whose function is not completely understood. Studies show that the BCR protein may act as a GTPase activating protein (GAP). GAPs turn off (inactivate) proteins called GTPases, which play an important role in chemical signaling within cells. Often referred to as molecular switches, GTPases can be turned on and off. They are turned on (active) when they are attached (bound) to a molecule called GTP and are turned off when they are bound to another molecule called GDP. The BCR protein inactivates a GTPase known as Rac1 by stimulating a reaction that turns the attached GTP into GDP. Through this activity, the BCR protein helps regulate the movement (migration) and function of cells. The BCR protein can also act as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions. BCR's kinase activity is likely involved in regulating signaling within cells, although its exact role is unclear. Health Conditions Related to Genetic Changes Chronic myeloid leukemia A genetic rearrangement (translocation) involving the BCR gene causes a type of cancer of blood-forming cells called chronic myeloid leukemia. This slow-growing cancer leads to an overproduction of abnormal white blood cells. Common features of the condition include excessive tiredness (fatigue), fever, weight loss, and an enlarged spleen. The translocation involved in this condition, written as t(9;22), fuses part of the ABL1 gene from chromosome 9 with part of the BCR gene from chromosome 22, creating an abnormal fusion gene called BCR-ABL1.
    [Show full text]
  • Myeloproliferative Neoplasms Panel by FISH
    Myeloproliferative Neoplasms Panel by FISH Indications for Ordering Eosinophilia Panel by FISH 2002378 • Diagnosis, prognosis, and monitoring of eosinophilic • Aids in diagnosis and classification of specific leukemias myeloproliferative neoplasms (MPNs) with eosinophilia in • Probes target: conjunction with cytogenetic testing: o FGFR1 translocations o Chronic myelogenous leukemia (CML): BCR-ABL1 o FIP1L1-PDGFRA region rearrangements positive o PDGFRB translocations o Myeloid and lymphoid neoplasms with eosinophilia and Chromosome FISH, Interphase 2002298 abnormalities of PDGFRA, PDGFRB, or FGFR1 • Specific FISH probes must be requested and include: • Monitor minimal residual disease (MRD) in MPNs o PDGFRA Test Description o PDGFRB o FGFR1 • Performed on bone marrow (BM) o BCR-ABL1 o Peripheral blood may be used but not preferred o inv(16) • Probes target: Myeloid Malignancies Mutation Panel by Next Generation o BCR-ABL1 fusion Sequencing 2011117 o FGFR1 translocations • Assess for single gene mutations, including substitutions o FIP1L1-PDGFRA region rearrangements and insertions and deletions that may have diagnostic, o PDGFRB translocations prognostic, and/or therapeutic significance • Each probe can be run as a panel or individually Disease Overview Tests to Consider Diagnostic issues Primary test • FISH analysis has several advantages over chromosome Myeloproliferative Disorders Panel by FISH 2002360 studies in MPN diagnosis • Limited role in the workup of myeloproliferative o More rapid turnaround time neoplasms in the setting of
    [Show full text]